VONVENDI: payments to doctors
Payments that named VONVENDI as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $34.5M
- Providers
- 615
- Transactions
- 911
- Average per transaction
- $37,842
The per-transaction average — $37,842 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 615 providers the average total is $56,056, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $31,351,628 | 90.9% |
| Shire North American Group Inc | $3,122,769 | 9.1% |